{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:54:37Z","timestamp":1790488477109,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jdiacomp.2023.108515","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T11:52:48Z","timestamp":1684929168000},"page":"108515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus"],"prefix":"10.1016","volume":"37","author":[{"given":"Anjay","family":"Rastogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2023.108515_bb0005","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3390\/ijms17070797","article-title":"Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension","volume":"17","author":"Mu\u00f1oz-Durango","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0010","series-title":"StatPearls [Internet]. Treasure Island (FL)","article-title":"Physiology, renin angiotensin system","author":"Fountain","year":"2022"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0015","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1093\/eurheartj\/ehy439","article-title":"Ten commandments of the 2018 ESC\/ESH HTN guidelines on hypertension in adults","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0020","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0030","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2022","journal-title":"Kidney Int."},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0035","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/diacare.28.suppl_1.S4","article-title":"Standards of medical care in diabetes","volume":"28","author":"American Diabetes A","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0040","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2147\/VHRM.S11816","article-title":"Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination","volume":"6","author":"Cagnoni","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0045","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40265-019-1064-1","article-title":"Management of hypertension in chronic kidney disease","volume":"79","author":"Pugh","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0050","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1681\/ASN.2004110919","article-title":"Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations","volume":"16","author":"Pohl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0055","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1161\/01.HYP.0000164577.81087.70","article-title":"Control of hypertension in adults with chronic kidney disease in the United States","volume":"45","author":"Peralta","year":"2005","journal-title":"Hypertension."},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0060","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0070","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0075","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0080","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0085","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000513119","article-title":"Dual blockade of the renin-angiotensin system: a strategy that should be reconsidered in cardiorenal diseases?","volume":"145","author":"Mei","year":"2021","journal-title":"Nephron"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0090","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4103\/1947-2714.147978","article-title":"Dual blockade of renin angiotensin system in reducing the early changes of diabetic retinopathy and nephropathy in a diabetic rat model","volume":"6","author":"Thangaraju","year":"2014","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0095","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1161\/01.CIR.96.9.3072","article-title":"Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats","volume":"96","author":"Menard","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0100","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Ontarget Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0105","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0110","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0115","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-0042-101242","article-title":"Disputes in the treatment of diabetic nephropathy: the dual blockade of renin-angiotensin system","volume":"124","author":"Grolla","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0120","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0125","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.ejheart.2004.09.005","article-title":"Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT","volume":"6","author":"Krum","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejheart.2007.12.006","volume":"10","author":"Weir","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12933-017-0547-1","article-title":"SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease","volume":"16","author":"Zou","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0140","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13300-013-0042-y","article-title":"Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus","volume":"4","author":"Bays","year":"2013","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0145","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0150","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0155","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0160","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0170","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0175","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0180","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/00325481.2015.1090295","article-title":"User\u2019s guide to mechanism of action and clinical use of GLP-1 receptor agonists","volume":"127","author":"Shaefer","year":"2015","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0185","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic kidney disease and risk management: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0190","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0195","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0200","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like Peptide-1 receptor agonists Semaglutide and Liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0205","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(20)30313-2","article-title":"Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials","volume":"8","author":"Mann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0210","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/ckj\/sfac069","article-title":"GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art","volume":"15","author":"Granata","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0215","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0220","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3389\/fendo.2019.00584","article-title":"Role of aldosterone and mineralocorticoid receptor in cardiovascular aging","volume":"10","author":"Gorini","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0225","first-page":"E388","article-title":"Characterization of aldosterone binding sites in circulating human mononuclear leukocytes","volume":"248","author":"Armanini","year":"1985","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0230","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1096\/fj.06-7970com","article-title":"Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis","volume":"21","author":"Caprio","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0235","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1046\/j.1523-1755.2000.00971.x","article-title":"Brain mineralocorticoid receptors and centrally regulated functions","volume":"57","author":"de Kloet","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0240","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/01.RES.71.3.503","article-title":"Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor","volume":"71","author":"Lombes","year":"1992","journal-title":"Circ Res"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0245","series-title":"StatPearls [Internet]. Treasure Island (FL)","article-title":"Physiology, aldosterone","author":"Scott","year":"2022"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0250","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ddr.21760","article-title":"Role of mineralocorticoid receptor antagonists in kidney diseases","volume":"82","author":"Patel","year":"2021","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0260","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0265","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0270","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of Baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0275","series-title":"Aldosterone-mineralocorticoid receptor: cell biology to translational medicine","article-title":"Potential benefit of mineralocorticoid receptor antagonists in kidney diseases","volume":"Vol. 811","author":"Barrera-Chimal","year":"2019"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0280","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","article-title":"Mineralocorticoid receptor antagonism in chronic kidney disease","volume":"6","author":"Georgianos","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0285","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension."},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0290","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0295","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.115.04889","article-title":"New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future","volume":"66","author":"Pitt","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0300","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","article-title":"Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0305","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0310","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0315","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0320","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0325","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110535","article-title":"Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease)","volume":"9","author":"Szczech","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0335","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0340","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2021","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0345","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0350","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0355","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000496681","article-title":"Chronic kidney disease: exploring value-based healthcare as a potential viable solution","volume":"47","author":"Busink","year":"2019","journal-title":"Blood Purif"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0360","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0365","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0370","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/dom.14696","article-title":"Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes","volume":"24","author":"DeFronzo","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0375","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1517\/13543784.10.5.943","article-title":"The spironolactone renaissance","volume":"10","author":"Doggrell","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0380","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0385","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.dsx.2017.08.003","article-title":"SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms","volume":"12","author":"Filippatos","year":"2018","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2023.108515_bb0390","series-title":"Kerendia (Finerenone) Prescribing Information","author":"Food and Drug Adminstration (FDA)","year":"2022"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723001137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872723001137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:18:39Z","timestamp":1761005919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872723001137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":78,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1056872723001137"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108515","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multimodal efforts to slow the progression of chronic kidney disease in patients with type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"108515"}}